Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study.
Adult
Case-Control Studies
Contraceptives, Oral, Combined
/ therapeutic use
Endometriosis
/ complications
Ethinyl Estradiol
/ therapeutic use
Female
Hormone Antagonists
/ therapeutic use
Humans
Nandrolone
/ analogs & derivatives
Ovarian Diseases
/ complications
Pelvic Pain
/ etiology
Treatment Outcome
Young Adult
Endometriosis
dienogest
endometrioma
ultrasound
Journal
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
ISSN: 1473-0766
Titre abrégé: Gynecol Endocrinol
Pays: England
ID NLM: 8807913
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
pubmed:
18
7
2019
medline:
20
11
2020
entrez:
18
7
2019
Statut:
ppublish
Résumé
Ovarian endometriomas are common manifestations of endometriosis. Surgical excision has been shown to potentially decrease ovarian reserves. In this prospective study, we included 81 patients with ovarian endometriosis. 40 were treated with 2 mg of dienogest daily (DNG) and 41 were treated with cyclic oral estro-progestins (ethinyl estradiol 30 mcg [EE] plus dienogest 2 mg) (DNG + EE). Aim of the study was the effect of the treatment on the size of the endometriotic cysts. Further, in the symptomatic patients, follow-up included an evaluation of chronic pain before and during treatment. Both treatments were able to significantly decrease the pain in symptomatic patients with no statistical differences. The mean visual analog scale score at enrollment was 65 ± 14 and 70 ± 18, and there was significant improvement (19 ± 15,
Identifiants
pubmed: 31311360
doi: 10.1080/09513590.2019.1640674
doi:
Substances chimiques
Contraceptives, Oral, Combined
0
Hormone Antagonists
0
Ethinyl Estradiol
423D2T571U
dienogest
46M3EV8HHE
Nandrolone
6PG9VR430D
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM